Table 3 Utility and cost parameters
Palivizumab/placebo (SE) | Distribution in PSA | Source | |
|---|---|---|---|
Utilities | |||
Baseline (age 0–17 years) | 0.950 (0.162) | Beta | Greenough et al. (2004) |
Baseline (age 18–24 years) | 0.982 (0.003) | Beta | Szende et al. (2014) |
Baseline (age 25–34 years) | 0.975 (0.003) | Beta | Szende et al. (2014) |
Baseline (age 35–44 years) | 0.949 (0.009) | Beta | Szende et al. (2014) |
Baseline (age 45–54 years) | 0.923 (0.010) | Beta | Szende et al. (2014) |
Baseline (age 55–64 years) | 0.901 (0.009) | Beta | Szende et al. (2014) |
Baseline (age 65–74 years) | 0.891 (0.007) | Beta | Szende et al. (2014) |
Baseline (age 75 years onwards) | 0.781 (0.014) | Beta | Szende et al. (2014) |
Decrement: RSV-H | 0.070 (0.014) | Beta | Greenough et al.(2004) |
Decrement: asthma | 0.048 (0.010) | Lognormal | Briggs et al. (2006) |
Decrement: allergic sensitization | 0.046 (0.009) | Lognormal | Brüggenjürgen et al. (2008) |
Direct costs | |||
Prophylaxis cost | € 2902 | Fixed | Synagis vial cost, Pedraz et al. (2003), Clinical expert input |
General ward hospital stay/day | € 591 (€ 118) | Gamma | Lázaro y de Mercado et al. (2006) |
Intensive care support/day | € 1041 (€ 208) | Gamma | Lázaro y de Mercado et al. (2006) |
Outpatient visit | € 21 (€ 4) | Gamma | Dal Negro et al. (2007) |
Asthma/year | € 744 (€ 149) | Gamma | Blasco Bravo et al. (2011) |
Allergy/year | € 198 (€ 40) | Gamma | Smith et al. (2005) |
RSV-H (pediatric ward), days | 7 (1.4) | Gamma | Medrano et al. (2010) |
RSV-H – ICU, days | 10 (2.0) | Gamma | Medrano et al. (2010) |
Risk of ICU admission, % | 30.4 (6.1) | Beta | Medrano et al. (2010) |
Delayed surgery (outpatient), GP visits | 4 (0.8) | Gamma | Expert opinion |
Delayed surgery (inpatient), days | 28 (5.6) | Gamma | Expert opinion |
Immediate surgery, days | 2.1 (0.42) length of stay in pediatric ward | Gamma | Altman et al. (2000) |
Indirect costs | |||
Missed work: Palivizumab administration, hours | 2 (0.4) | Gamma | Assumption |
Missed work: MA-RSV, hours | 2 (0.4) | Gamma | Assumption |
Missed work: RSV-H, hours | 57 (11.5) | Gamma | Medrano et al. (2010), Assumption |
Asthma/year | € 495 (€ 99) | Gamma | Blasco Bravo et al. (2011) |
Allergy/year | € 259 (€ 52) | Gamma | Smith et al. (2005) |
Nosocomial infection: risk, % | 6.1 (0.6) | Beta | Ehlken et al. (2005) |
Nosocomial infection (pediatric ward), days | 14 (2.8) | Gamma | Assumption, Expert opinion |
Absence from work/hour | € 20 (€ 4) | Gamma | Anuario Estadístico de Espana (2017; Spanish statistical yearbook) |